MicroPort NeuroTech Steps Up Competition in Brain Vascular Devices With New Embolic Agent Trial

MicroPort NeuroTech Limited (HK:2172) announced an update on their ongoing clinical study.

Study Overview

The clinical study “a Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Controlled Registration Trial of the Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation” aims to test a new liquid embolic agent from MicroPort NeuroTech for treating brain arteriovenous malformations and related fistulas. The goal is to show that this new product is not worse than an existing global device in terms of safety and effectiveness, supporting future regulatory approval and expanding MicroPort NeuroTech’s neurovascular portfolio.

Intervention/Treatment

The trial compares a new liquid embolic agent developed by MicroPort NeuroTech to the Onyx Liquid Embolic System, a well-known embolization device. Both are minimally invasive devices injected into abnormal brain vessels to block blood flow and reduce the risk of bleeding or other complications during treatment.

Study Design

This is an interventional study with random assignment of patients into two groups: one receives the MicroPort liquid embolic agent and the other receives Onyx. It uses a parallel group design, meaning both treatments are tested at the same time in different patients. The study is open-label, so doctors and patients know which product is used. The main aim is treatment-focused, measuring safety and clinical benefit over several follow-up visits.

Study Timeline

The study was first submitted on 16 January 2025, signaling the formal start of the clinical and regulatory process. The trial is currently recruiting, with follow-up visits planned up to 12 months after the first procedure, which will define the primary completion milestone when initial outcome data are available. The last update to the record was submitted on 30 December 2025, showing the protocol and status are actively maintained and suggesting ongoing operational progress toward full completion and data readout at a later date.

Market Implications

For investors, this randomized head-to-head study against Onyx is important because it benchmarks MicroPort NeuroTech’s technology directly against a leading incumbent product in neurovascular care. Positive non-inferiority results could support regulatory approvals in China and possibly other markets, strengthen MicroPort NeuroTech’s product mix in high-value stroke and cerebrovascular treatment, and improve pricing power and hospital penetration. That, in turn, could support revenue growth expectations and margin expansion for HK:2172, improving sentiment after each meaningful update or milestone. Conversely, delays in recruitment or inconclusive data could weigh on the stock near term. Competitors in the embolic space, including international medtech leaders already selling Onyx and similar systems, may face price pressure and slower share gains in China if MicroPort’s device proves comparable and wins local procurement tenders. Overall, the active status and recent update suggest MicroPort is executing on its pipeline, which is usually viewed positively by long-term medtech investors who focus on recurring procedure volumes and product lifecycle.

The study is currently ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about HK:2172’s potential, visit the MicroPort NeuroTech Limited drug pipeline page.